Evidence map›Paper›PMID 39585844›Full record

ArticlePloS one2024

Improving HIV testing, linkage, and retention in care among South African men through U = U messaging: A study protocol for two sequential hybrid type 1 effectiveness-implementation randomized controlled trials.

Andrew Medina-Marino, Nkosiyapha Sibanda, Mary Putt, Dvora Joseph Davey, Phillip Smith, Harsha Thirumurthy, Linda-Gail Bekker, Alison Buttenheim

Abstract readClinical Trial Protocol
In one paragraph

Article in PloS one, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors.

Andrew Medina-MarinoDesmond Tutu HIV Centre, University of Cape Town, Cape Town, South Africa.ORCID 0000-0002-2691-982X
Nkosiyapha SibandaDesmond Tutu HIV Centre, University of Cape Town, Cape Town, South Africa.
Mary PuttDepartment of Biostatistics, Epidemiology and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America.
Dvora Joseph DaveyDesmond Tutu HIV Centre, University of Cape Town, Cape Town, South Africa.
Phillip SmithDesmond Tutu HIV Centre, University of Cape Town, Cape Town, South Africa.
Harsha ThirumurthyDepartment of Medical Ethics and Health Policy, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States of America.
Linda-Gail BekkerDesmond Tutu HIV Centre, University of Cape Town, Cape Town, South Africa.
Alison ButtenheimCenter for Health Incentives and Behavioral Economics, University of Pennsylvania, Philadelphia, PA, United States of America.

Funding

Improving HIV testing, linkage, and retention in care for men through U=U messagingR01MH129223 · NIMH · DESMOND TUTU HIV FOUNDATION · PI Alison Meredith Buttenheim, Andrew Medina-Marino · 2022 to 2026
$2.7M
Khulani Siphile Siphuhle Training Program in South Africa (KiSS-TP)D43TW012497 · FIC · DESMOND TUTU HIV FOUNDATION · PI BEKKER, LINDA-GAIL, COHEN, CRAIG R · 2023 to 2025
$1.0M
FIC NIH HHS D43 TW012497NIMH NIH HHS R01 MH129223
6 · The paper itself

Abstract

backgroundIncreasing HIV testing and treatment coverage among people living with HIV (PLHIV) is essential for achieving global HIV epidemic control. However, compared to women, cis-gender heterosexual men living with HIV are significantly less likely to know their HIV status, initiate anti-retroviral therapy (ART) and achieve viral suppression. This is particularly true in South Africa, where men are also at increased risk of mortality resulting from AIDS-related illnesses. While there is growing knowledge of Treatment as Prevention or the concept Undetectable = Untransmittable (U = U) among PLHIV in Western and high-income countries, the reach and penetration of the U = U message in sub-Saharan Africa remains limited, and few studies have evaluated the impact of accessible and relatable U = U messages on ART initiation and adherence. To address these gaps, rigorous evaluations of interventions that incorporate U = U messages are needed, especially among men in high prevalence settings.

methodsBuilding on our U = U messages that we previously developed for men using behavioral economics insights and a human-centered design, we will conduct two sequential hybrid type 1 effectiveness-implementation trials to evaluate the impact of U = U messages on men's uptake of community-based HIV testing and ART initiation (Trial 1), and retention in care and achievement of viral suppression (Trial 2). For trial 1, a cluster randomized trial will be implemented with HIV testing service site-days (each day at one testing site) randomized to U = U or standard-of-care (SoC) messages inviting men to test for HIV. For trial 2, an individual-level randomized control trial will be implemented, with men initiating ART at six government clinics randomized to receive U = U counselling or SoC treatment adherence messaging. We will incorporate a multi-method evaluation to inform future implementation of U = U messaging interventions. The study will be conducted in the Buffalo City Metro Health District of the Eastern Cape Province and in the Cape Town Metro Health District in the Western Cape Province in South Africa. DISCUSSION: These trials are the first to rigorously evaluate the impact of U = U messaging on HIV testing uptake, ART initiation and achievement of viral suppression among African men. If effective, these messaging interventions can shape global HIV testing, treatment and adherence counselling guidelines and practices.

Indexed as

HIV InfectionsHIV TestingAdultAnti-HIV AgentsHumansMaleMass ScreeningRandomized Controlled Trials as TopicRetention in CareSouth AfricaAnti-HIV Agents

Identifiers

PMID39585844
PMCPMC11588259

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.